Dushyant Singh Dahiya1, Abhilash Perisetti2, Neil Sharma3,4, Sumant Inamdar5, Hemant Goyal6,7, Amandeep Singh8, Laura Rotundo9, Rajat Garg8, Chin-I Cheng10, Sailaja Pisipati11, Mohammad Al-Haddad12, Madhusudhan Sanaka8. 1. Department of Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, USA. dush.dahiya@gmail.com. 2. Parkview Cancer Institute, Fort Wayne, IN, USA. 3. Division of Interventional Oncology & Surgical Endoscopy (IOSE), Parkview Cancer Institute, Fort Wayne, IN, USA. 4. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA. 5. Department of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 6. The Wright Center for Graduate Medical Education, Scranton, PA, USA. 7. Department of Internal Medicine, Mercer University School of Medicine, Macon, GA, USA. 8. Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH, USA. 9. Section of Digestive Diseases, Yale New Haven Hospital, New Haven, CT, USA. 10. Department of Statistics, Actuarial and Data Science, Central Michigan University, Mt Pleasant, MI, USA. 11. Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA. 12. Division Chief and Professor of Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA.
Abstract
BACKGROUND: We identified trends of inpatient therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in the United States (US), focusing on outcomes related to specific patient demographics. METHODS: The National Inpatient Sample was utilized to identify all adult inpatient ERCP in the US between 2007-2018. Trends of utilization and adverse outcomes were highlighted. P-values ≤ 0.05 were considered statistically significant. RESULTS: We noted a rising trend for total inpatient ERCP in the US from 126,921 in 2007 to 165,555 in 2018 (p = 0.0004), with a significant increase in utilization for Blacks, Hispanics, and Asians. Despite an increasing comorbidity burden [Charlson Comorbidity Index (CCI) score ≥ 2], the overall inpatient mortality declined from 1.56% [2007] to 1.46% [2018] without a statistically significant trend (p = 0.14). Moreover, there was a rising trend of inpatient mortality for Black and Hispanic populations, while a decline was noted for Asians. After a comparative analysis, we noted higher rates of inpatient mortality for Blacks (2.4% vs 1.82%, p = 0.0112) and Hispanics (1.17% vs 0.83%, p = 0.0052) at urban teaching hospitals between July toand September compared to the October to June study period; however, we did not find a statistically significant difference for the Asian cohort (1.9% vs 2.10%, p = 0.56). The mean length of stay (LOS) decreased from 7 days in 2007 to 6 days in 2018 (p < 0.0001), while the mean total hospital charge (THC) increased from $48,883 in 2007 to $85,909 in 2018 (p < 0.0001) for inpatient ERCPs. Compared to the 2015-2018 study period, we noted higher rates of post-ERCP pancreatitis (27.76% vs 17.25%, p < 0.0001) from 2007-2014. CONCLUSION: Therapeutic ERCP utilization and inpatient mortality were on the rise for a subset of the American minority population, including Black and Hispanics.
BACKGROUND: We identified trends of inpatient therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in the United States (US), focusing on outcomes related to specific patient demographics. METHODS: The National Inpatient Sample was utilized to identify all adult inpatient ERCP in the US between 2007-2018. Trends of utilization and adverse outcomes were highlighted. P-values ≤ 0.05 were considered statistically significant. RESULTS: We noted a rising trend for total inpatient ERCP in the US from 126,921 in 2007 to 165,555 in 2018 (p = 0.0004), with a significant increase in utilization for Blacks, Hispanics, and Asians. Despite an increasing comorbidity burden [Charlson Comorbidity Index (CCI) score ≥ 2], the overall inpatient mortality declined from 1.56% [2007] to 1.46% [2018] without a statistically significant trend (p = 0.14). Moreover, there was a rising trend of inpatient mortality for Black and Hispanic populations, while a decline was noted for Asians. After a comparative analysis, we noted higher rates of inpatient mortality for Blacks (2.4% vs 1.82%, p = 0.0112) and Hispanics (1.17% vs 0.83%, p = 0.0052) at urban teaching hospitals between July toand September compared to the October to June study period; however, we did not find a statistically significant difference for the Asian cohort (1.9% vs 2.10%, p = 0.56). The mean length of stay (LOS) decreased from 7 days in 2007 to 6 days in 2018 (p < 0.0001), while the mean total hospital charge (THC) increased from $48,883 in 2007 to $85,909 in 2018 (p < 0.0001) for inpatient ERCPs. Compared to the 2015-2018 study period, we noted higher rates of post-ERCP pancreatitis (27.76% vs 17.25%, p < 0.0001) from 2007-2014. CONCLUSION: Therapeutic ERCP utilization and inpatient mortality were on the rise for a subset of the American minority population, including Black and Hispanics.
Authors: E J Williams; S Taylor; P Fairclough; A Hamlyn; R F Logan; D Martin; S A Riley; P Veitch; M L Wilkinson; P R Williamson; M Lombard Journal: Endoscopy Date: 2007-09 Impact factor: 10.093
Authors: Sheila D Rustgi; Sunil P Amin; Michelle K Kim; Satish Nagula; Nikhil A Kumta; Christopher J DiMaio; Paolo Boffetta; Aimee L Lucas Journal: World J Gastrointest Endosc Date: 2019-02-16
Authors: Anna Tavakkoli; Amit G Singal; Akbar K Waljee; James M Scheiman; Caitlin C Murphy; Sandi L Pruitt; Lei Xuan; Richard S Kwon; Ryan J Law; Grace H Elta; Phyllis Wright-Slaughter; Thomas S Valley; Nisa Kubiliun; Hari Nathan; Joel H Rubenstein; B Joseph Elmunzer Journal: Cancer Med Date: 2019-05-14 Impact factor: 4.452
Authors: Paul T Kröner; Mohammad Bilal; Ronald Samuel; Shifa Umar; Marwan S Abougergi; Frank J Lukens; Massimo Raimondo; David L Carr-Locke Journal: Endosc Int Open Date: 2020-05-25
Authors: Marianna Galeazzi; Paolo Mazzola; Breanna Valcarcel; Giuseppe Bellelli; Marco Dinelli; Giulio Maria Pasinetti; Giorgio Annoni Journal: BMC Gastroenterol Date: 2018-03-14 Impact factor: 3.067